SMILE: Results of FDA Premarket Approval Clinical Trial

被引：0
|
作者：
Bitzer, Michaela
机构：
来源：
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE | 2020年 / 237卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：1386 / 1387
页数：2
相关论文
共 50 条
  • [31] Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
    Downing, Nicholas S.
    Aminawung, Jenerius A.
    Shah, Nilay D.
    Krumholz, Harlan M.
    Ross, Joseph S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (04): : 368 - 377
  • [32] FDA approval
    不详
    GERIATRICS, 2001, 56 (11) : 16 - 16
  • [33] FDA approval
    不详
    GERIATRICS, 2001, 56 (09) : 16 - 16
  • [34] FDA approval
    不详
    GERIATRICS, 2001, 56 (03) : 20 - 20
  • [35] Valuing Clinical Strategies Immediately After FDA Approval
    Bennett, Charles L.
    Knopf, Kevin B.
    JAMA NETWORK OPEN, 2025, 8 (03)
  • [36] LEGAL-ASPECTS OF PREMARKET APPROVAL OF MEDICAL DEVICES
    SHAPIRO, MH
    FOOD AND DRUG LAW JOURNAL, 1983, 38 (03): : 205 - 219
  • [37] Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia
    Davis, Michael C.
    Miller, Brian J.
    Kalsi, Jasmeet K.
    Birkner, Thomas
    Mathis, Mitchell V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (26): : 2503 - 2506
  • [38] Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
    Ayalew Tefferi
    Animesh Pardanani
    Blood Cancer Journal, 14
  • [39] Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
    Tefferi, Ayalew
    Pardanani, Animesh
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [40] Characteristics and use of patient-reported outcomes of clinical trials for high-risk neurological medical devices that received FDA premarket approval from 2001 to 2022
    Ryan, Morgan E.
    Srivastava, Siddharth
    Wan, Lin
    Yang, Guang
    Zhang, Bo
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 37
12345